Sentinel node biopsy safe for vulvar squamous cell cancer

Sentinel node biopsy safe for vulvar squamous cell cancer
For women with squamous cell carcinoma of the vulva, sentinel lymph node biopsy may be safely used in place of inguinal femoral lymphadenectomy, according to research published online July 2 in the Journal of Clinical Oncology.

(HealthDay) -- For women with squamous cell carcinoma (SCC) of the vulva, sentinel lymph node (SLN) biopsy may be safely used in place of inguinal femoral lymphadenectomy, according to research published online July 2 in the Journal of Clinical Oncology.

To determine the safety of SLN as a replacement for inguinal femoral lymphadenectomy, Charles F. Levenback, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a Gynecologic Oncology Group study involving 452 women with SCC where the primary tumor was limited to the vulva and the tumor size was between 2 and 6 cm with at least 1-mm invasion. Participants underwent intraoperative lymphatic mapping, biopsy of SLNs, and inguinal femoral lymphadenectomy.

The researchers identified at least one SLN in 418 of the women. A total of 132 women were node positive, with 8.3 percent of these being false-negatives. Immunohistochemical analysis of the SLNs identified 23 percent of true positives with a sensitivity of 91.7 percent and a false-negative predictive value of 3.7 percent. The false-negative predictive value was even lower, at 2.0 percent, in women with tumors smaller than 4 cm.

" biopsy is a reasonable alternative to inguinal femoral lymphadenectomy in selected women with of the vulva," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Survival hope for melanoma patients thanks to new vaccine

3 hours ago

(Medical Xpress)—University of Adelaide researchers have discovered that a new trial vaccine offers the most promising treatment to date for melanoma that has spread, with increased patient survival rates and improved ability ...

New clinical trial launched for advance lung cancer

6 hours ago

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer – marking a new era of research into personalised medicines ...

User comments